| Literature DB >> 30879282 |
Nari Shin1, Gyung Mo Son2,3, Dong-Hoon Shin4, Myeong-Sook Kwon2,3, Byung-Soo Park2, Hyun-Sung Kim2, Dongryeol Ryu5, Chi-Dug Kang6.
Abstract
PURPOSE: We evaluated the relationship of cancer-associated fibroblasts (CAFs) and desmoplastic reactions with cancer invasiveness and long-term outcomes in patients with colorectal cancer (CRC).Entities:
Keywords: Cancer-associated fibroblasts; Colorectal neoplasms; Desmoplasia; Survival; Wound healing
Year: 2019 PMID: 30879282 PMCID: PMC6425246 DOI: 10.3393/ac.2018.09.10
Source DB: PubMed Journal: Ann Coloproctol ISSN: 2287-9714
Fig. 1.Histological categorization of desmoplastic reactions and cancer-associated fibroblast (CAF) maturation. (A) Mature desmoplasia is composed of elongated collagen fibers and spindle-shaped CAF cells. (B) Immature desmoplasia is composed of myxoid components, keloidlike collagen bundles, and large plump CAFs (H&E, ×40).
Patient characteristics (n = 151)
| Characteristic | Intratumoral CAF | Invasive front CAF | ||||
|---|---|---|---|---|---|---|
| Mature (n = 87) | Immature (n = 64) | P-value | Mature (n = 91) | Immature (n = 60) | P-value | |
| Clinical factors | ||||||
| Age, ≥70 yr | 26 (29.9) | 17 (26.6) | 0.655 | 26 (28.6) | 17 (28.3) | 0.975 |
| Male sex | 46 (52.9) | 42 (65.6) | 0.116 | 51 (56.0) | 37 (61.7) | 0.493 |
| BMI, ≥25 kg/m2 | 30 (34.5) | 16 (25.0) | 0.211 | 31 (34.1) | 15 (25.0) | 0.236 |
| Serum CEA, >5 mg/dL | 31 (35.6) | 25 (39.1) | 0.666 | 33 (36.3) | 23 (38.3) | 0.797 |
| Colon obstruction | 30 (34.5) | 27 (42.2) | 0.334 | 31 (34.1) | 26 (43.3) | 0.250 |
| Cancer sideness | ||||||
| Right | 26 (29.9) | 21 (32.8) | 0.701 | 26 (28.6) | 21 (35.0) | 0.404 |
| Left | 61 (70.1) | 43 (67.2) | 65 (71.4) | 39 (65.0) | ||
| Pathologic factors | ||||||
| Tumor size, >5 cm | 37 (42.5) | 34 (53.1) | 0.197 | 37 (40.7) | 34 (56.7) | 0.054 |
| Pathologic stage | 0.154 | 0.095 | ||||
| I | 18 (20.7) | 9 (14.1) | 20 (22.0) | 7 (11.7) | ||
| II | 26 (29.9) | 24 (37.5) | 24 (26.4) | 26 (43.3) | ||
| III | 31 (35.6) | 28 (43.3) | 36 (39.6) | 23 (38.3) | ||
| IV | 12 (13.8) | 3 (4.7) | 11 (12.1) | 4 (6.7) | ||
| Histologic grade | 0.118 | 0.156 | ||||
| Well differentiated (G1) | 7 (8.4) | 4 (6.3) | 9 (10.5) | 2 (3.3) | ||
| Moderately differentiated (G2) | 71 (85.5) | 59 (93.7) | 73 (84.9) | 57 (95.0) | ||
| Poorly differentiated (G3) | 5 (6.0) | 0 (0) | 4 (4.7) | 1 (1.7) | ||
| Molecular factors | ||||||
| Cytoplasmic CEA | 66 (75.9) | 49 (76.6) | 0.920 | 67 (73.6) | 48 (80.0) | 0.368 |
| P53 accumulation | 55 (63.2) | 35 (54.7) | 0.291 | 55 (60.4) | 35 (58.3) | 0.796 |
| EGFR overexpression | 28 (40.0) | 13 (23.6) | 0.053 | 30 (41.1) | 11 (21.2) | 0.019 |
| KRAS mutation | 21 (32.3) | 18 (32.7) | 0.961 | 21 (30.4) | 18 (35.3) | 0.574 |
| BRAF mutation | 0 (0) | 1 (2.3) | 0.249 | 0 (0) | 1 (2.4) | 0.230 |
| MSI-high | 8 (15.7) | 5 (11.4) | 0.541 | 10 (18.5) | 3 (7.3) | 0.116 |
Values are presented as number (%).
CAF, cancer-associated fibroblast; BMI, body mass index; CEA, carcinoembryonic antigen; EGFR, epidermal growth factor receptor; KRAS, K-ras proto-oncogene; BRAF, B-raf proto-oncogene; MSI, microsatellite instability.
Fig. 2.Correlation of epidermal growth factor receptor (EGFR) overexpression and cancer-associated fibroblast maturation in the tumor stroma of colorectal cancer.
Distribution of cancer-associated fibroblast (CAF) maturity and cancer invasiveness factors according to colorectal cancer stage (n = 151)
| Variable | Stage I (n = 27) | Stage II (n = 50) | Stage III (n = 59) | Stage IV (n = 15) | P-value |
|---|---|---|---|---|---|
| Intratumoral CAF | 0.154 | ||||
| Mature | 18 (66.7) | 26 (52.0) | 31 (52.5) | 12 (80.0) | |
| Immature | 9 (33.3) | 24 (48.0) | 28 (47.5) | 3 (20.0) | |
| Invasive front CAF | 0.095 | ||||
| Mature | 20 (74.1) | 24 (48.0) | 36 (61.0) | 11 (73.3) | |
| Immature | 7 (25.9) | 26 (52.0) | 23 (39.0) | 4 (26.7) | |
| Lymphatic invasion | 1 (3.7) | 3 (6.0) | 14 (23.7) | 6 (40.0) | 0.001 |
| Vascular invasion | 0 (0) | 2 (4.0) | 7 (11.9) | 2 (13.3) | 0.135 |
| Perineural invasion | 0 (0) | 11 (22.2) | 22 (37.3) | 8 (53.3) | <0.001 |
| Tumor budding | 8 (29.6) | 23 (46.0) | 35 (59.3) | 8 (53.3) | 0.076 |
| Tumor growth pattern | 0.389 | ||||
| Expanding type | 9 (33.3) | 11 (22.0) | 10 (16.9) | 4 (26.7) | |
| Infiltrating type | 18 (66.7) | 39 (78.0) | 49 (83.1) | 11 (73.3) |
Values are presented as number (%).
Cancer-associated fibroblast (CAF) maturation and cancer invasion (n = 151)
| Variable | Intratumoral CAF maturation | Invasive front CAF maturation | ||||
|---|---|---|---|---|---|---|
| Mature CAF (n = 87) | Immature CAF (n = 64) | P-value | Mature CAF (n = 91) | Immature CAF (n = 60) | P-value | |
| Lymphatic invasion | 19 (21.8) | 5 (7.8) | 0.024 | 16 (17.6) | 8 (13.3) | 0.650 |
| Vascular invasion | 8 (9.2) | 3 (4.7) | 0.358 | 6 (6.6) | 5 (8.3) | 0.754 |
| Perineural invasion | 23 (26.4) | 18 (28.1) | 0.854 | 23 (25.3) | 18 (30.0) | 0.577 |
| Tumor budding | 45 (51.7) | 29 (45.3) | 0.511 | 50 (54.9) | 24 (40.0) | 0.096 |
| Infiltrating growth | 60 (69.0) | 57 (89.1) | 0.003 | 64 (70.3) | 53 (88.3) | 0.029 |
| T status (3-4) | 61 (70.1) | 49 (76.6) | 0.460 | 60 (65.9) | 50 (83.3) | 0.024 |
| N status (1-2) | 43 (49.4) | 31 (48.4) | 0.904 | 47 (51.6) | 27 (45.0) | 0.506 |
Values are presented as number (%).
Five-year overall survival and systemic recurrence according to cancer-associated fibroblast (CAF) maturation in patients with colorectal cancer (n = 151)
| CAF | Overall survival | Odds ratio | 95% CI | P-value | Systemic recurrence | Odds ratio | 95% CI | P-value |
|---|---|---|---|---|---|---|---|---|
| Intratumoral CAF (mature vs. immature) | 76.7% vs. 87.5% | 1.925 | 0.848–4.371 | 0.118 | 23.9% vs. 29.1% | 0.921 | 0.486–1.746 | 0.801 |
| Invasive front CAF (mature vs. immature) | 77.9% vs. 88.3% | 2.060 | 0.876–4.847 | 0.098 | 22.4% vs. 31.9% | 0.798 | 0.421–1.513 | 0.489 |
CAF, cancer-associated fibroblast; CI, confidence interval.
Fig. 3.Five-year overall survival of patients with colorectal cancer by significant prognostic factors. EGFR, epidermal growth factor receptor; CEA, carcinoembryonic antigen.
Fig. 4.Five-year systemic recurrence of colorectal cancer by significant prognostic factors. EGFR, epidermal growth factor receptor; CEA, carcinoembryonic antigen.
Univariate and multivariate analyses of 5-year overall survival and systemic recurrence for patients with colorectal cancer (n = 151)
| Variable | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI | P-value | OR | 95% CI | P-value | |
| Overall survival | ||||||
| T status (3–4) | 4.014 | 1.566–10.235 | 0.004 | - | - | - |
| N status (1–2) | 3.654 | 1.774–7.530 | <0.001 | 5.363 | 1.572–18.291 | 0.007 |
| Lymphatic invasion | 2.340 | 1.160–4.722 | 0.018 | - | - | - |
| Tumor budding | 2.386 | 1.079–5.275 | 0.032 | 2.286 | 0.892–5.855 | 0.085 |
| EGFR overexpression | 0.506 | 0.253–1.013 | 0.054 | - | - | - |
| Age, ≥70 yr | 2.455 | 1.295–4.656 | 0.006 | 2.286 | 1.275–6.572 | 0.011 |
| Serum CEA, >5 mg/dL | 4.075 | 2.083–7.971 | < 0.001 | - | - | - |
| Systemic recurrence | ||||||
| T status (3–4) | 5.037 | 2.141–11.850 | < 0.001 | 2.148 | 1.147–4.021 | 0.017 |
| N status (1–2) | 3.204 | 1.743–5.890 | < 0.001 | - | - | - |
| Lymphatic invasion | 2.980 | 1.619–5.483 | < 0.001 | 2.815 | 1.487–5.330 | 0.001 |
| Perineural invasion | 2.087 | 1.179–3.693 | 0.012 | - | - | - |
| Vascular invasion | 2.634 | 1.182–5.871 | 0.018 | - | - | - |
| EGFR overexpression | 2.612 | 1.113–3.638 | 0.021 | 2.033 | 1.097–3.770 | 0.024 |
| Age, ≥70 yr | 3.095 | 1.764–5.430 | 0.001 | 2.148 | 1.147–4.021 | 0.017 |
| Serum CEA, >5 mg/dL | 1.965 | 1.121–3.452 | 0.018 | - | - | - |
OR, odds ratio; CI, confidence interval; EGFR, epidermal growth factor receptor; CEA, carcinoembryonic antigen.
Fig. 5.Network analysis of Spearman’s coefficients of correlation. The blue line reflects significant correlation with a coefficient >0.2. The red line reflects reverse correlation with a coefficient <–0.2. CEA, carcinoembryonic antigen; MSI, microsatellite instability; BMI, body mass index; EGFR, epidermal growth factor receptor; CAF, cancer-associated fibroblast.